Roche is committed to eradicate cervical cancer globally by
increasing screening accuracy, efficiency and access for all women
Addressing unmet global need
Cervical cancer is a preventable disease, but is one of the most common cancers in women.
Cervical cancer is one of the greatest threats to women's health. Every minute, one woman is diagnosed with cervical cancer. In 2018, more than 300,000 women died of cervical cancer. We can do more to address this problem.
Estimated age-standardized incidence rates (World) in 2018, cervical cancer, all ages
Majority of disease burden is in Low & Middle Income Countries (LMIC)
“Nine out of 10 women who die from cervical cancer live in low- and middle-income countries.”
"Women living with HIV have four to ten times greater chance of developing cervical cancer when infected with HPV than HIV-negative women, making cervical cancer a major threat to the health of women living with HIV."
Some of the most vulnerable women in our world are dying unnecessarily. In poorer countries, women are often diagnosed with cervical cancer at a more advanced stage, where the opportunity for a cure is low. This is compounded by a lack of access to life-saving treatment in settings where the burden and need are highest.
There is a global call for action to meet proposed cervical cancer prevention goals by 2030.
"Every country must introduce and scale-up HPV
screening for women between 30 and 49 years old,
and ensure appropriate treatment and follow-up.1"
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, 24 September 2018
"Elimination of cervical cancer as a global health
problem is within reach for all countries. We
know what works, and we now need to scale up
our actions to prevent and control this disease."
Dr Princess Nono Simelela, Assistant Director-General for Family, Women,
Children and Adolescents, WHO
A combination of vaccination and HPV-based screening programs can prevent cervical cancer.
- HPV is the underlying cause of >99% of cervical cancer2
- Modern HPV DNA testing identifies women at risk so that they can be monitored for early treatment when needed